Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES015-2
- Development stage
- Unknown
- Lead developer
- Elpiscience
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ES015-2 is a bifunctional fusion protein designed to simultaneously target the programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β) pathways. Developed by Elpiscience, the molecule consists of a monoclonal antibody against PD-L1 fused to the extracellular domain of the TGF-β receptor II (TGF-βRII), which acts as a trap for TGF-β. By inhibiting PD-L1, ES015-2 aims to restore T-cell activity against tumor cells, while the TGF-β trap component neutralizes TGF-β in the tumor microenvironment, thereby reducing immunosuppression, fibrosis, and epithelial-mesenchymal transition (EMT). This dual mechanism is intended to overcome resistance to anti-PD-(L)1 monotherapies, particularly in cold tumors where TGF-β signaling is a dominant immune evasion strategy.
- Other names
- PD-L1/TGF-beta bispecific fusion protein
02
Targets
KLRD1 (CD94/NKG2A complex)KLRC2 (CD94/NKG2C receptor)
Beyond the preview
Go deeper on ES015-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ES015-2.